The Prognostic Significance of Tumor-Infiltrating Lymphocytes for Primary Melanoma Varies by Sex.
By: Andrew J Sinnamon, Cimarron E Sharon, Yun Song, Madalyn G Neuwirth, David E Elder, Xiaowei Xu, Emily Y Chu, Michael E Ming, Douglas L Fraker, Phyllis A Gimotty, Giorgos C Karakousis

Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA. Electronic address: andrew.sinnamon@uphs.upenn.edu.
2017-10-13; doi: 10.1016/j.jaad.2018.02.066
Abstract

Background

The immune response to melanoma is manifested locally by tumor-infiltrating lymphocytes (TILs). Men and women are known to have varying patterns of immunity, yet sex-specific prognostic implications of TILs have not been explored.

Methods

Patients with clinically localized primary melanoma ≥0.76mm in Breslow thickness who underwent sentinel lymph node (SLN) biopsy at our institution were identified. Association between TILs (absent, nonbrisk, and brisk) and SLN positivity was evaluated using logistic regression. Overall survival (OS) was evaluated by TILs status and sex.

Results

Among 1,367 patients identified, 794 were men. TILs were brisk in 143 lesions, nonbrisk in 903, and absent in 321, which did not vary by sex (p=0.71). SLN positivity was associated with TILs among men (brisk 3.8%, nonbrisk 16.9%, absent 26.6%, p<0.001). In contrast, there was no association between SLN positivity and TILs among women (p=0.49). Interaction between brisk TILs and sex on SLN positivity was significant (p=0.029). Among men, presence of brisk TILs was associated with prolonged OS (p=0.038) but not after adjustment for SLN status (p=0.42). There was no association between TILs status and OS among women.

Limitations

Findings from this single-institution study have yet to be validated by other research groups.

Conclusions

The implications of TILs in predicting SLN positivity appear to be more relevant for men than women.



Copyright © 2018. Published by Elsevier Inc.

PMID:29518458






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements